Patents by Inventor Jonathan Brotchie

Jonathan Brotchie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of motor fluctuations
    Patent number: 9668995
    Abstract: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: June 6, 2017
    Assignee: Motac Neuroscience Limited
    Inventors: Jonathan Brotchie, Michael Hill
  • Treatment of dyskinesia
    Patent number: 8198294
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: June 12, 2012
    Assignee: Motac Neuroscience Limited
    Inventor: Jonathan Brotchie
  • Treatment of Motor Fluctuations
    Publication number: 20110178178
    Abstract: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.
    Type: Application
    Filed: March 31, 2011
    Publication date: July 21, 2011
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventors: Jonathan Brotchie, Michael Hill
  • Treatment of dyskinesia
    Patent number: 7935718
    Abstract: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: May 3, 2011
    Assignee: Motac Neuroscience Limited
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Treatment of dyskinesia
    Publication number: 20100184797
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Application
    Filed: August 31, 2009
    Publication date: July 22, 2010
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventor: Jonathan Brotchie
  • Treatment of dyskinesia
    Publication number: 20060069039
    Abstract: The present invention relates to the treatment of dyskinesia with compounds of General Formula (I) such as topiramate. The compound may be topiramate or a derivative thereof. The dyskinesia may be associated with a basil ganglia-related movement disorder such as parkinsonism and may also arise as a side-effect of other therapeutic agents (e.g. L-DOPA).
    Type: Application
    Filed: September 1, 2003
    Publication date: March 30, 2006
    Inventors: Alan Crossman, Michael Hill, Jonathan Brotchie, Montague Silverdale
  • Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
    Publication number: 20050261282
    Abstract: The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy for pakinsonism.
    Type: Application
    Filed: September 11, 2003
    Publication date: November 24, 2005
    Applicant: Motac Neuroscience Limited Williams House
    Inventors: Alan Crossman, Michael Hill, Jonathan Brotchie
  • Treatment of dyskinesia
    Publication number: 20050245587
    Abstract: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
    Type: Application
    Filed: October 28, 2004
    Publication date: November 3, 2005
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Treatment of dyskinesia
    Publication number: 20050009856
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Application
    Filed: April 7, 2004
    Publication date: January 13, 2005
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventor: Jonathan Brotchie
  • Treatment of dyskinesia
    Patent number: 6740659
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: May 25, 2004
    Assignee: Motac Neuroscience Limited
    Inventor: Jonathan Brotchie
  • Treatment of motor fluctuations
    Publication number: 20040067956
    Abstract: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.
    Type: Application
    Filed: June 27, 2003
    Publication date: April 8, 2004
    Inventors: Jonathan Brotchie, Michael Hill
  • Diagnosis of the parkinsonian condition
    Publication number: 20030139438
    Abstract: The present invention relates to a method of diagnosis of the parkinsonian condition in presymptomatic subjects. Additionally, the invention relates to a method for the differential diagnosis of early Parkinson's disease and differentiating Parkinson's disease patients from patients with other movement disorders.
    Type: Application
    Filed: November 21, 2002
    Publication date: July 24, 2003
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman, Erwan Bezard
  • Treatment of movement disorders with metabotropic glutamate receptors antagonist
    Publication number: 20030109504
    Abstract: The present invention relates to the use of compounds, which inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in combination with another therapeutic agent and surprisingly reduce the extent and incidence of side effects (e.g. dyskinesia) associated with such therapeutic agents.
    Type: Application
    Filed: November 14, 2002
    Publication date: June 12, 2003
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Treatment of dyskinesia
    Publication number: 20030060478
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Application
    Filed: August 2, 2002
    Publication date: March 27, 2003
    Applicant: THE VICTORIA UNIVERSITY OF MANCHESTER
    Inventor: Jonathan Brotchie
  • Treatment of dyskinesia
    Publication number: 20020137669
    Abstract: The invention relates to the use of compounds which inhibit selectively mu opioid receptor activity, or activation, for the treatment of dyskinesia (which, for example, may arise as a side effect of L-DOPA therapy). The compounds used are preferably mu opioid receptor antagonists such as cyprodime.
    Type: Application
    Filed: May 20, 2002
    Publication date: September 26, 2002
    Applicant: THE VICTORIA UNIVERSITY OF MANCHESTER
    Inventor: Jonathan Brotchie
  • Treatment of dyskinesia
    Patent number: 6455536
    Abstract: The invention is to a method for the treatment of dyskinesia which comprises administering a selective mu opioid receptor antagonist.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: September 24, 2002
    Assignee: The Victoria University of Manchester
    Inventor: Jonathan Brotchie